Literature DB >> 20098330

Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.

Tomoaki Ichikawa1, Kazuhiro Saito, Naoki Yoshioka, Akihiro Tanimoto, Takehiko Gokan, Yasuo Takehara, Takeshi Kamura, Toshifumi Gabata, Takamichi Murakami, Katsuyoshi Ito, Shinji Hirohashi, Akihiro Nishie, Yoko Saito, Hiroaki Onaya, Ryohei Kuwatsuru, Atsuko Morimoto, Koji Ueda, Masayo Kurauchi, Josy Breuer.   

Abstract

OBJECTIVES: To prospectively evaluate the safety and efficacy of combined unenhanced and gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance (MR) imaging compared with unenhanced MR imaging and triphasic contrast-enhanced spiral computed tomography (CT) for the detection and characterization of focal liver lesions.
MATERIALS AND METHODS: The study was reviewed and approved by the institutional review board at each of the 15 centers involved in the study, and informed written consent was given by all patients. In total, 178 patients with suspected focal hepatic lesions (based, in most patients, on CT, tumor marker and ultrasound examinations) underwent combined MR imaging with a single, rapid injection of Gd-EOB-DTPA 0.025 mmol/kg, including T1-weighted dynamic and delayed MR images 20 to 40 minutes postinjection. Triphasic contrast-enhanced CT, the comparator examination, was performed within 4 weeks of MR imaging. Standard of references (SOR) were resection histopathology and intraoperative ultrasonography, or combined CT during arterial portography and CT hepatic arteriography; in cases where, although the major lesions were treated, some lesion(s) were not treated, follow-up superparamagnetic iron oxide-enhanced MR imaging was additionally performed. All images were assessed for differences in lesion detection and characterization (specific lesion type) by on-site readers and 3, blinded (off-site) reviewers. All adverse events (AEs) occurring within 72 hours after Gd-EOB-DTPA administration were reported.
RESULTS: Overall, 9.6% of patients who received Gd-EOB-DTPA reported 21 drug-related AEs. A total of 151 patients were included in the efficacy analysis. Combined MR imaging showed statistically higher sensitivity in lesion detection (67.5%-79.5%) than unenhanced MR imaging (46.5%-59.1%; P < 0.05 for all). Combined MR imaging also showed higher sensitivity in lesion detection than CT (61.1%-73.0%), with the results being statistically significant (P < 0.05) for on-site readers and 2 of 3 blinded readers. Higher sensitivity in lesion detection with combined MR imaging compared with CT was also clearly demonstrated in the following subgroups: lesions with a diameter <or=20 mm (lesions <or=10 mm: 38.0%-55.4% vs. 26.1%-47.3%, respectively; lesions 10-20 mm: 71.1%-87.3% vs. 65.7%-78.4%, respectively); in cirrhotic patients (64.5%-75.4% vs. 54.5%-70.3%, respectively); and in patients with hepatocellular carcinoma (66.6%-78.6% vs. 59.1%-71.6%, respectively). Combined MR imaging demonstrated a higher proportion of correctly characterized lesions (50.5%-72.1%) than unenhanced MR imaging (30.2%-50.0%; P < 0.05 for all), whereas there were no significant differences compared with CT (49.0%-68.1%), except for one blinded reader (P < 0.05).
CONCLUSION: In this study, hepatocyte-specific Gd-EOB-DTPA was shown to be safe and to improve the detection and characterization of focal hepatic lesions compared with unenhanced MR imaging. When compared with spiral CT, Gd-EOB-DTPA enhanced MRI seems to be beneficial especially for the detection for smaller lesions or hepatocellular carcinoma underlying cirrhotic liver.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20098330     DOI: 10.1097/RLI.0b013e3181caea5b

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  69 in total

1.  Small (≤ 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT.

Authors:  J Hwang; S H Kim; M W Lee; J Y Lee
Journal:  Br J Radiol       Date:  2011-12-13       Impact factor: 3.039

2.  Effects of gadoxetic acid on liver elasticity measurement by using magnetic resonance elastography.

Authors:  Utaroh Motosugi; Tomoaki Ichikawa; Hironobu Sou; Katsuhiro Sano; Ali Muhi; Richard L Ehman; Tsutomu Araki
Journal:  Magn Reson Imaging       Date:  2011-09-19       Impact factor: 2.546

3.  Biliary reflux detection in anomalous union of the pancreatico-biliary duct patients.

Authors:  Suk Keu Yeom; Seung Wha Lee; Sang Hoon Cha; Hwan Hoon Chung; Bo Kyung Je; Baek Hyun Kim; Jong Jin Hyun
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

4.  The essence of the Japan Radiological Society/Japanese College of Radiology Imaging Guideline.

Authors:  Yasuyuki Yamashita; Sadayuki Murayama; Masahiro Okada; Yoshiyuki Watanabe; Masako Kataoka; Yasushi Kaji; Keiko Imamura; Yasuo Takehara; Hiromitsu Hayashi; Kazuko Ohno; Kazuo Awai; Toshinori Hirai; Kazuyuki Kojima; Shuji Sakai; Naofumi Matsunaga; Takamichi Murakami; Kengo Yoshimitsu; Toshifumi Gabata; Kenji Matsuzaki; Eriko Tohno; Yasuhiro Kawahara; Takeo Nakayama; Shuichi Monzawa; Satoru Takahashi
Journal:  Jpn J Radiol       Date:  2016-01       Impact factor: 2.374

5.  Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging.

Authors:  Katsutoshi Sugimoto; Fuminori Moriyasu; Junji Shiraishi; Kazuhiro Saito; Junichi Taira; Toru Saguchi; Yasuharu Imai
Journal:  Eur Radiol       Date:  2012-01-24       Impact factor: 5.315

6.  Enhancement patterns and pseudo-washout of hepatic haemangiomas on gadoxetate disodium-enhanced liver MRI.

Authors:  Bohyun Kim; Jae Ho Byun; Hyoung Jung Kim; Hyung Jin Won; So Yeon Kim; Yong Moon Shin; Pyo Nyun Kim
Journal:  Eur Radiol       Date:  2015-05-02       Impact factor: 5.315

7.  Hepatocellular carcinoma: clinical significance of signal heterogeneity in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging.

Authors:  Nobuhiro Fujita; Akihiro Nishie; Yuichiro Kubo; Yoshiki Asayama; Yasuhiro Ushijima; Yukihisa Takayama; Koichiro Moirta; Ken Shirabe; Shinichi Aishima; Hiroshi Honda
Journal:  Eur Radiol       Date:  2014-07-26       Impact factor: 5.315

8.  Factors predicting aggressiveness of non-hypervascular hepatic nodules detected on hepatobiliary phase of gadolinium ethoxybenzyl diethylene-triamine-pentaacetic-acid magnetic resonance imaging.

Authors:  Tsutomu Kanefuji; Toru Takano; Takeshi Suda; Kouhei Akazawa; Takeshi Yokoo; Hiroteru Kamimura; Kenya Kamimura; Atsunori Tsuchiya; Masaaki Takamura; Hirokazu Kawai; Satoshi Yamagiwa; Hidefumi Aoyama; Minoru Nomoto; Shuji Terai
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

9.  Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease.

Authors:  Ying Ding; Sheng-Xiang Rao; Tao Meng; Caizhong Chen; Renchen Li; Meng-Su Zeng
Journal:  Eur Radiol       Date:  2014-01-26       Impact factor: 5.315

10.  Fusion imaging of contrast-enhanced ultrasound and contrast-enhanced CT or MRI before radiofrequency ablation for liver cancers.

Authors:  Xiao-Wan Bo; Hui-Xiong Xu; Dan Wang; Le-Hang Guo; Li-Ping Sun; Xiao-Long Li; Chong-Ke Zhao; Ya-Ping He; Bo-Ji Liu; Dan-Dan Li; Kun Zhang
Journal:  Br J Radiol       Date:  2016-09-14       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.